title: Reduction of experimental vein graft intimal hyperplasia by ketanserin.
abstract: Intimal hyperplasia is considered to be the result of smooth muscle cell proliferation. Experimental vein grafts (VG) in the rabbit develop intimal hyperplasia and a contractile response to serotonin (5-HT), mediated by a 5-HT2 receptor. 5-HT is known to stimulate smooth muscle cell proliferation in vitro and therefore may be linked to the development of intimal hyperplasia. This study examines the effect of a 5-HT2 antagonist, ketanserin (KT) on vein graft morphology and function at 14 and 28 days after grafting. Forty-three New Zealand White rabbits underwent common carotid interposition bypass grafting. Twenty-two were treated with KT (0.86 mg/kg/day po) 5 days prior to surgery and thereafter until harvest. The remaining 21 animals acted as controls. VG were harvested at 14 (VG14) and 28 (VG28) days for histology or vasoreactivity. Twenty-three VG were harvested by pressure fixation and the midportions of the grafts were examined by videomorphometry. Standard isometric tension studies in response to serotonin and norepinephrine (NE) were performed on the rings from the remaining 20 VG. Contralateral external jugular veins (CV) from both groups were studied to assess the functional toxicity of KT. There were no toxic effects to KT noted. KT therapy did not affect the functional activity of the CV at 14 or 28 days when compared to controls. When compared to controls, KT significantly reduced the intimal thickness (49 +/- 11 vs 113 +/- 24 microns; P = 0.04) and there was an increase in luminal area (16.89 +/- 2.13 vs 8.41 +/- 1.59 mm2; P < 0.02) in VG28 only.(ABSTRACT TRUNCATED AT 400 WORDS)
authors.affiliation: Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
authors.forename: M F
authors.initials: MF
authors.lastname: Massey
authors.forename: M G
authors.initials: MG
authors.lastname: Davies
authors.forename: E
authors.initials: E
authors.lastname: Svendsen
authors.forename: M L
authors.initials: ML
authors.lastname: Klyachkin
authors.forename: L B
authors.initials: LB
authors.lastname: Schwartz
authors.forename: L
authors.initials: L
authors.lastname: Barber
authors.forename: R L
authors.initials: RL
authors.lastname: McCann
authors.forename: P O
authors.initials: PO
authors.lastname: Hagen
mesh_terms: D000818:Animals; D006965:Hyperplasia; D007650:Ketanserin / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology*; D009638:Norepinephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011817:Rabbits; D012701:Serotonin / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects; D014680:Veins / Q000473:pathology / Q000637:transplantation*
chemical_list: D012701:Serotonin; D011189:Potassium Chloride; D007650:Ketanserin; D009638:Norepinephrine